PTC Therapeutics insider sold 1,638 shares while PTC Therapeutics stock fell 1.36 percent
Published on 10/08/2026 at 22:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- A PTC Therapeutics insider sold 1,638 shares on October 5, 2026, while PTCT stock fell 1.36 percent in euros on October 8.
- Second-quarter 2026 revenue reached USD 360.52 million, up 101.50 percent year over year, and net income was USD 83.50 million.
- PTCT traded at EUR 55.74 at Lang & Schwarz on October 8, 2026, versus a prior close of EUR 56.51.
- The next earnings date is October 22, 2026, while PTC expects to complete the ST-920 regulatory submission in Q4 2026.
On October 5, 2026, a PTC Therapeutics insider sold 1,638 shares, while PTC Therapeutics stock was down 1.36 percent at Lang & Schwarz on October 8, 2026. MarketBeat reported the transaction and identified the seller as vice president Mark Elliott Boulding.
Three recent milestones
On July 30, 2026, PTC Therapeutics reported second-quarter revenue of USD 360.52 million and diluted earnings per share of USD 0.92. Revenue increased 101.50 percent from the prior-year quarter, while the company recorded net income of USD 83.50 million, according to Investing.com.
On September 21, 2026, PTC completed its acquisition of ST-920, a one-time administered gene therapy for Fabry disease. The company said a rolling biologics license application submission is expected to be completed in Q4 2026, according to PTC Therapeutics.
On September 22, 2026, Cantor Fitzgerald raised its price target from USD 130.00 to USD 137.00 and maintained an Overweight rating, according to Investing.com.
What does the pipeline add?
ST-920 gives PTC another late-stage rare-disease program, but the next regulatory milestone remains the expected Q4 2026 submission. The September acquisition therefore adds a development asset rather than an immediately commercial product, leaving execution and regulatory timing as the measurable near-term test.
Dates investors can track
The next dated milestones are October 22, 2026, for PTC Therapeutics' quarterly results, and Q4 2026 for the expected ST-920 submission. The October reporting date is listed by Investing.com, while the regulatory timing comes from PTC Therapeutics.
PTCT trades below its prior close
PTCT was trading at EUR 55.74 at Lang & Schwarz on October 8, 2026, down 1.36 percent versus the prior close of EUR 56.51. The primary Nasdaq listing was quoted at USD 62.56 on October 8, 2026, in after-hours trading, with a market capitalization of USD 5.2 billion and a 52-week range of USD 61.23 to USD 90.87. The further course of trading is shown by the continuously updated real-time quote of PTC Therapeutics stock.
PTC Therapeutics stock at a glance
- Company: PTC Therapeutics, Inc.
- ISIN: US69366J2006
- Ticker: PTCT
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026: EUR 55.74
- Change versus prior close: minus 1.36 percent
- Prior close Lang & Schwarz: EUR 56.51
- Market capitalization: USD 5.2 billion as of October 8, 2026
- 52-week range: USD 61.23-90.87 as of October 8, 2026
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: October 22, 2026
Market context: Market report Nasdaq Composite.
